<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004613</url>
  </required_header>
  <id_info>
    <org_study_id>12-1379</org_study_id>
    <nct_id>NCT02004613</nct_id>
  </id_info>
  <brief_title>Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery</brief_title>
  <acronym>Decade</acronym>
  <official_title>Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator goal is to evaluate the effects of intraoperative and postoperative
      dexmedetomidine sedation (versus placebo after cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation Outcome of patients assigned to dexmedetomidine or placebo.</measure>
    <time_frame>3 to 90 Days after surgery</time_frame>
    <description>To measure whether dexmedetomidine sedation decreases the incidence of atrial arrhythmias.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation Outcome of patients assigned to dexmedetomidine or placebo</measure>
    <time_frame>3 to 90 days after surgery</time_frame>
    <description>To measure whether dexmedetomidine sedation reduces postoperative delirium.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">965</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline administration matching dexmedetomidine rate of infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administration matching dexmedetomidine rate of infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-85 years old;

          2. Scheduled for cardiac surgery with bypass (CABG, valve, or combined);

          3. Able to provide a written informed consent;

          4. Hemodynamically stable (heart rate&gt;= 55).

        Exclusion Criteria:

          1. Sick sinus syndrome or Wolff-Parkinson-White syndrome

          2. Atrio-ventricular block

          3. Hypersensitivity or known allergy to dexmedetomidine

          4. Hepatic disease, e.g. twice the normal level of liver enzymes

          5. AF within 1 preoperative month;

          6. Permanent pacemaker;

          7. Use of amiodarone or dexmedetomidine within the last 30 days;

          8. Patients with an ejection fraction under 30% or who had severe heart failure

          9. Myocardial infarction in the previ¬ous 7 days;

         10. Body mass index =&lt; 40 (BMI= mass (kg) / height (m)2);

         11. Those tak¬ing clonidine within last 48 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alparslan Turan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Main</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Alparslan Turan</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

